Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Intermittent Oral CM082 (Vorolanib) in wAMD
NCT03710863Phase 2Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Nov 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in exudative macular degeneration, sponsored by AnewPharma Company, Ltd. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03710863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710863.